Presentation on theme: "Impact of IMPACT Patients’ Demographic Characteristics and Outcomes An analysis of FHI Initial ART Sites Philippe Chiliade, MD, MHA."— Presentation transcript:
Impact of IMPACT Patients’ Demographic Characteristics and Outcomes An analysis of FHI Initial ART Sites Philippe Chiliade, MD, MHA
Goals of the Analysis Demographic characteristics of patients enrolled in FHI initial ART programs Patients’ disposition: retained in care, lost to follow-up, known death, transfer out Immunologic outcomes Helping in moving forward
Data Sources (1) FHI started implementing ART programs with IMPACT funding in 4 countries: Cambodia, Ghana, Kenya, and Rwanda. Databases with baseline and follow-up patient-level data were created to monitor the characteristics of the populations served as well as the volume and outcomes of these ART services.
Data Sources (2) Countries and Sites selections: - Initial ART sites to allow longitudinal analysis - Reasonable completeness of data - Internal validation of data Data elements selections: - Demographics, disposition, CD4 - Similar definition of data elements
Limitations of the analysis Retrospective data analysis Sites were selected for their data quality Little is known about the reasons and clinical outcomes of those lost to follow-up Initial sites were often large secondary or tertiary health facilities
Selected FHI-supported ART Sites # Sites ART Start Date # Patients Cambodia15/031,362 Ghana45/035,844 Rwanda42/031,707
Patients Characteristics % male Age % WHO III or IV Baseline CD4 cells / mm3 Cambodia47%3594%59 Ghana37%3861%114 Rwanda36%3959%150
Patients Characteristics %female%maleAge % WHO III or IV Baseline CD4 cells / mm3 Cambodia53%47%3594%59 Ghana63%37%3861%114 Rwanda64%36%3959%150
Analysis of Care Disposition (1) Retention in care In all 3 countries retention in care was related to baseline CD4 cell count In Ghana and Rwanda, women are 33% less likely to be retained In Ghana, any level of education was negatively related with retention
Analysis of Care Disposition (2) Known deaths Over 70% of known deaths occurred within the first 6 months of ART initiation Lost to follow-up (LTFU) Little is known about the reasons and clinical outcome of those LTFU
Immunologic Response In all 3 countries the median CD4 of the cohort increased with time on ART. That increase of CD4 over time was not driven by the removal from the cohort of sicker patients dying or being lost to follow-up. After starting ART, the percentage of patients with CD4 < 50 and CD4 < 200 rapidly decreased.
Immunologic Outcomes % with CD4 < 50 At Baseline At 6 months At 12 months At 18 months Cambod.42%3%2%3% Ghana26%3%3%2% Rwanda14%
Immunologic Outcomes % with CD4 < 200 At Baseline At 6 months At 12 months At 18 months Cambod.84%48%36%31% Ghana75%28%18%15% Rwanda74%
The Way Forward (1) Bring patients in care earlier, before their disease become too advanced Need to better understand factors related to early death and lost to follow-up Clinical and immunologic staging are adequate to inform when to start ART but virologic measures are key to monitor the response to ART
The Way Forward (2) Monitor frequencies and patterns of drug resistance and use this information in the development of care guidelines Develop (existing) local laboratory capacity Monitor quality of care and adopt quality improvement approaches
Acknowledgements FHI HQ Walter Obiero, Ya Diul Mukadi, Inoussa Kabore FHI Cambodia Amrita Mathew, Ngak Song FHI Ghana Yussif Ahmed Abdul Rahman, Richard Amenyah, Kwasi Torpey FHI Rwanda Misti McDowell, Fabienne Shumbusho
Your consent to our cookies if you continue to use this website.